Last reviewed · How we verify
GSK1120212 plus everolimus — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK1120212 plus everolimus (GSK1120212 plus everolimus) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK1120212 plus everolimus TARGET | GSK1120212 plus everolimus | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK1120212 plus everolimus CI watch — RSS
- GSK1120212 plus everolimus CI watch — Atom
- GSK1120212 plus everolimus CI watch — JSON
- GSK1120212 plus everolimus alone — RSS
Cite this brief
Drug Landscape (2026). GSK1120212 plus everolimus — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk1120212-plus-everolimus. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab